José Ramón Azpiri López

Dr. José Ramón Azpiri López


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
DGDionicio A. Galarza-Delgado
Dionicio A. Galarza-Delgado
JLJosé Ramón Azpiri López
José Ramón Azpiri López
ICIris J. Colunga-Pedraza
Iris J. Colunga-Pedraza
NGNatalia Guajardo-Jauregui
Natalia Guajardo-Jauregui
ARAlejandra B. Rodriguez-Romero
Alejandra B. Rodriguez-Romero
AGAndrea C. Garza-Acosta
Andrea C. Garza-Acosta

14 January 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
JLJosé Ramón Azpiri López
José Ramón Azpiri López
DGDionicio A. Galarza-Delgado
Dionicio A. Galarza-Delgado
ICIris J. Colunga-Pedraza
Iris J. Colunga-Pedraza
RARosa I. Arvizu-Rivera
Rosa I. Arvizu-Rivera
JGJesus Alberto Cardenas-de la Garza
Jesus Alberto Cardenas-de la Garza
NGNatalia Guajardo-Jauregui
Natalia Guajardo-Jauregui

15 August 2016 in Cureus
Verified
Journal Article
Open access
PDF file
EMEdgar Monroy
Edgar Monroy
JLJosé Ramón Azpiri López
José Ramón Azpiri López
CPCuauhtémoc De La Peña
Cuauhtémoc De La Peña
CCCarlos Cardona
Carlos Cardona
MHMiguel Hinojosa
Miguel Hinojosa
JAJose Assad
Jose Assad
Pulmonary vein isolation using robotic radiosurgery system CyberKnife is a new non-invasive treatment of atrial fibrillation, currently in clinical phase. Robotic radiosurgical pulmonary vein isolation (RRPVI) uses stereotactic, non-invasive (painless) pinpoint radiation energy delivery to a small, precise area to accomplish ablation. The purpose of this report is to describe the finding of an increase in the enhancement of the left atrium demonstrated with the use of cardiac magnetic resonance imaging using late gadolinium enhancement (LGE-CMR) as a result of RRPVI in the first case in the world in humans using CyberKnife as a treatment for paroxysmal atrial fibrillation (PAF).

23 July 2024 in RMD Open
Verified
Journal Article
Open access
PDF file
GKGeorge Karpouzas
George Karpouzas
SOSarah R Ormseth
Sarah R Ormseth
PRPiet Leonardus Cornelis Maria van Riel
Piet Leonardus Cornelis Maria van Riel
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
ACAlfonso Corrales
Alfonso Corrales
GKGeorge Kitas
George Kitas
Objectives Chronic inflammation promotes cardiovascular risk in rheumatoid arthritis (RA). Biological disease-modifying antirheumatic drugs (bDMARDs) improve disease activity and cardiovascular disease outcomes. We explored whether bDMARDs influence the impact of disease activity and inflammatory markers on long-term cardiovascular risk in RA. Methods We studied 4370 participants without cardiovascular disease in a 10-country observational cohort of patients with RA. Endpoints were (1) major adverse cardiovascular events (MACE) encompassing myocardial infarction, stroke and cardiovascular death; and (2) any ischaemic cardiovascular events (iCVE) including MACE plus revascularisation, angina, transient ischaemic attack and peripheral arterial disease. Results Over 26 534 patient-years, 239 MACE and 362 iCVE occurred. The interaction between 28-joint Disease Activity Score with C-reactive protein (DAS28-CRP) and bDMARD use was significant for MACE (p=0.017), suggesting the effect of DAS28-CRP on MACE risk differed among bDMARD users (n=515) and non-users (n=3855). DAS28-CRP (per unit increase) is associated with MACE risk in bDMARD non-users (HR 1.21 (95% CI 1.07 to 1.37)) but not users (HR 0.69 (95% CI 0.40 to 1.20)). The interaction between CRP (per log unit increase) and bDMARD use was also significant for MACE (p=0.011). CRP associated with MACE risk in bDMARD non-users (HR 1.16 (95% CI 1.04 to 1.30)), but not users (HR 0.65 (95% CI 0.36 to 1.17)). No interaction was observed between bDMARD use and DAS28-CRP (p=0.167) or CRP (p=0.237) for iCVE risk. Conclusions RA activity and inflammatory markers associated with risk of MACE in bDMARD non-users but not users suggesting the possibility of biological-specific benefits locally on arterial wall independently of effects on systemic inflammation.

1 February 2021 in Archives of Medical Research
Verified
Journal Article
Closed access
HRHumberto Rodríguez-Reyes
Humberto Rodríguez-Reyes
SLSusano Lara-Vaca
Susano Lara-Vaca
AOAna Ochoa-Guzmán
Ana Ochoa-Guzmán
ECErwin Chiquete
Erwin Chiquete
AAArturo Abundes-Velasco
Arturo Abundes-Velasco
JZJosé G. Zúñiga-Sedano
José G. Zúñiga-Sedano

28 July 2023 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
DGDionicio Angel Galarza-Delgado
Dionicio Angel Galarza-Delgado
JLJosé Ramón Azpiri López
José Ramón Azpiri López
NGNatalia Guajardo-Jauregui
Natalia Guajardo-Jauregui
JGJesus Alberto Cardenas-de la Garza
Jesus Alberto Cardenas-de la Garza
AGAndrea Nallely Garza-Cisneros
Andrea Nallely Garza-Cisneros
ICIris Jazmin Colunga-Pedraza
Iris Jazmin Colunga-Pedraza
Background: Systemic inflammation, documented before rheumatoid arthritis (RA) diagnosis, is associated with accelerated atherosclerosis. We aimed to compare the prevalence of carotid plaque (CP) in RA patients in the first five years since diagnosis and healthy controls, and to determine disease characteristics associated with the presence of subclinical atherosclerosis in RA patients.Methods: This was a cross-sectional study. We recruited 60 RA patients in the first five years since diagnosis and 60 matched healthy controls. Carotid ultrasound was performed to detect the presence of CP and measure carotid-intima media thickness (cIMT). Subclinical atherosclerosis was considered as the presence of CP and/or increased cIMT. Distribution was evaluated with the Kolmogorov-Smirnov test. Comparisons were made with Chi-square or Fisher’s exact test for qualitative variables and Student’s t or Mann-Whitney’s U test for quantitative variables. A p-value < 0.05 was considered significant.Results: There were no differences in the demographic characteristics between RA patients and controls. The mean disease duration was 2.66 ± 1.39 years. A higher prevalence of CP (30.0% vs. 11.7%,p = 0.013), bilateral CP (18.3% vs. 3.3%,p = 0.008), increased cIMT (30.0% vs. 6.7%,p = 0.001), and subclinical atherosclerosis (53.3% vs. 18.3%,p = < 0.001) was found in RA patients. RA patients with subclinical atherosclerosis were older (56.70 years vs. 50.00 years,p = 0.002), presented a higher prevalence of dyslipidemia (53.1% vs. 14.3%,p = 0.002), and higher prevalence of classification in moderate-high disease activity category measured by DAS28-CRP (68.8% vs. 35.7%,p = 0.010). The latter variable persisted independently associated with subclinical atherosclerosis in the binary logistic regression (OR 6.11, 95% CI 1.51–24.70,p = 0.011).Conclusions: In the first five years since diagnosis, higher prevalence of subclinical atherosclerosis, including CP was found in RA patients. Carotid ultrasound should be considered part of the systematic CVR evaluation of RA at the time of diagnosis.